Industry Verticals »

All Categories

Insights »

About TMR »

Polypill Products Market

Polypill Products Market (Application: Cardiovascular, Diabetes Mellitus, Anti-infective, and Others; and Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027

Demand for Polypill Products to Scale New Heights as Studies Focus on Reducing Side Effects

The healthcare sector worldwide continues to embrace new medical treatments, therapies, and drugs. At present, cardiovascular diseases are considered to be the leading causes of death worldwide due to which, research and development activities pertaining to the treatment of an array of cardiovascular diseases have gained considerable momentum. Although international guidelines advocate the adoption of statins, aspirin, and pressure-lowering therapy for individuals with a history of cardiovascular condition, the adoption of these medications is relatively low. Multiple clinical trials have revealed that the combination of these medications with a polypill product is likely to improve systolic blood pressure, adherence, and low-density lipoprotein cholesterol.

Although the demand for polypill products is expected to witness steady growth during the forecast period, mounting safety concerns surrounding the use of polypill products could hamper its adoption. Research and development activities within the polypill products market are largely focused on minimizing the side effects and investigating the consequences of non-adherence to polypill products in comparison with individual medication. Thus, due to a surge in the prevalence of chronic diseases across the world, the demand for polypill products is projected to witness notable growth in the coming years. At the back of these factors, the global polypill products market is expected to reach market value of ~US$ 35 Bn by the end of 2027.

polypill products market infographic

Efforts to Improve Medication Adherence to Increase Demand for Polypill Products

High cholesterol and high blood pressure are some of the leading causes of cardiovascular deaths worldwide. Although there are treatments and medications available to address these conditions, they are left undertreated particularly in the underdeveloped and developing regions. The lack of adequate prescription and poor medication adherence are some of the leading factors as to why high cholesterol and high blood pressure are undertreated across the world. One of the potential methods to enhance medication adherence that is currently being investigated is the combination of one or more medications into a polypill.

Some of the major factors that are likely to boost the adoption of polypill products during the forecast period include lower dosage of different medications, which, in turn are projected to reduce the side effects. In addition, players operating in the current polypill products market are expected to advertise polypill products as an easy to remember medication and convenience as the USP to improve their sales. In addition, polypill products have also emerged as a cost-effective medication alternative and likely to replace therapies that require multiple medications.

Despite factors that are likely to increase the demand for polypill products in the coming years, the potential side-effects, overtreatment, undesirable interaction of different medication, and low dosing flexibility are some of the factors that could hinder the demand.

Advent of 3D Printed Drugs to Boost Polypill Products Market

Novel technologies such as 3D printing have played a key role in revolutionizing manufacturing processes in various industries, including automotive, aerospace, and dental. The narrative stands true within the healthcare sector wherein 3D printing is gradually making its mark. Most recently, 3D printing is increasingly being used to develop personalized drugs with improved reliability. The exceptional capability of 3D printing to develop medication with high degree of precision particularly in tune with the requirement of patients is expected to increase the adoption of 3D printing in the polypill products market. Several pharmaceutical companies are inclined toward adopting 3D printing medicines with different drug compounds such as polypills. The growing awareness regarding the benefits of 3D printed medicines is likely to influence the demand for 3D printed polypill products in the coming years.

While new technologies continue to make inroads in the healthcare sector, research and development activities will continue to accelerate the development of new polypill products. Several studies within the polypill products market aim toward the discovery of new polypill products and the potential benefits of the same. For instance, a recent study that is published in the New England Journal of Medicine reveals that polypill products have significant potential in lowering cholesterol and blood pressure among individuals suffering from cardiovascular problems.

polypill products market segmentation

Analysts’ Viewpoint

The global polypill products market is expected to grow at a sluggish CAGR of ~2% during the forecast period. Some of the leading factors that are expected to contribute to market growth include a high prevalence of cardiovascular diseases worldwide, gradual adoption of new technologies, including 3D printing to develop polypill products, lower medication cost compared to multiple medications, and research & development activities. Companies operating in the current market landscape should focus on research and development to improve the efficacy of polypill products and simultaneously lower the development costs. The advent of the 3D printing technology could open up new avenues for players in the polypill products market in the coming years.

Polypill Products Market: Overview

  • According to Transparency Market Research’s latest report on the global polypill products market for the historical period 2017–2018 and forecast period 2019–2027, high incidence and prevalence of chronic diseases such as cardiovascular and diabetes mellitus boost the growth of the global polypill products market. Moreover, low cost of products is projected to drive the global polypill products market during the forecast period.
  • According to the report, the global polypill products market was valued at US$ 29.7 Bn in 2018 and is anticipated to expand at a CAGR of ~2% from 2019 to 2027

Rise in Prevalence of Chronic Diseases and Increase in Focus on R&D: Key Drivers

  • Sedentary lifestyle and unhealthy diet have increased the prevalence and incidence of chronic diseases. According to the American Heart Association, cardiovascular diseases is the leading cause of death across the globe. According to the World Health Organization (WHO), cardiovascular diseases accounted for an estimated 17.9 million deaths across the world in 2016. This number is expected to increase to 23.6 million by 2030.
  • Increase in the global geriatric population, which is more prone to chronic diseases, is expected to drive the growth of the global polypill products market. According to the Global Burden of Cardiovascular Diseases (2015), the prevalence of stroke increases above 40 years of age.
  • Combination of multiple drugs in one dosage form, high adherence among the elderly population, and rise in utilization of polypill products are the major advantages offered by polypill products over other formulations
  • The factors mentioned above drive the demand for new polypill products. Industry players are investing in research & development to develop and introduce new polypill products to address the need and demand, which in turn is likely to augment the global polypill products market.

Low Cost and Patient Compliance Propel Polypill Products Market

  • Polypill is a fixed dose combination used in the treatment of various chronic diseases. This combination pharmacotherapy offers the potential to decrease the incidence and prevalence of cardiovascular and other diseases.
  • Cost of product and treatment is a major factor that influences the selection of treatment. Therefore, low cost of polypill products is boosting adoption.

Patent Expiry and Introduction of Generic Products to Hamper Polypill Products Market

  • Launch of new generic polypill products hampers the global polypill products market. In May 2017, the U.S. Food and Drug Administration approved a generic version of the anti-cholesterol drug Vytorin.
  • A number of products will go off patent in the U.S. and Europe in 2021, 2022, and 2025. Patent expiry of products affects market revenue, which in turn is likely to restrain the global polypill products market.

Polypill Products Market: Competition Landscape

  • This report profiles major players in the global polypill products market based on various attributes and recent developments
  • The global polypill products market is highly fragmented, with the presence of a number of international as well as regional players
  • Leading players operating in the global polypill products market are 
    • Pfizer, Inc.
    • AstraZeneca
    • Merck & Co., Inc. (Merck Sharp & Dohme Corp)
    • Janssen Pharmaceuticals, Inc. (Johnson & Johnson)
    • Dr. Reddy’s Laboratories Ltd.
    • Cipla, Inc.
    • Cadila Pharmaceuticals
    • Grupo Ferrer International,
    • S.A
    • Gebro Pharma GmbH
    • Gilead Sciences, Inc.
    • Takeda Pharmaceutical Company Limited

Polypill Products Market: Key Developments

  • Key players in the global polypill products market are engaged in regulatory approvals, technologically advanced products, launch of new products, and acquisition & collaborative agreements with other companies. These strategies are aimed at addressing unmet needs in the market, strengthening the product portfolio, and investing in research & development. A few expansion strategies adopted by players operating in the global polypill products market are:
    • In January 2020, AstraZeneca announced that the supplemental New Drug Application for Lynparza (olaparib) in combination with bevacizumab had been accepted and granted Priority Review in the U.S. for the treatment of ovarian cancer
    • In December 2019, the U.S. Food and Drug Administration accepted Pfizer’s supplemental New Drug Application (sNDA) for BRAFTOVI (encorafenib) in combination with ERBITUX (cetuximab)
    • In September 2019, Merck & Co., Inc. announced the pivotal study phase 3 RECARBRIO (imipenem 500 mg, cilastatin 500 mg, and relebactam 250 mg)
    • In June 2019, Janssen Pharmaceuticals, Inc. announced collaboration with the University of California, Berkeley (UC Berkeley) and the University of California, San Francisco (UCSF) to expand the data science research in healthcare
  • The report on the global polypill products market discussed individual strategies, followed by company profiles of manufacturers of polypill products. The competition landscape section has been included in the report to provide readers with a dashboard view and a company market share analysis of key players operating in the global polypill products market.

Polypill Products Market - Segmentation

Application

Cardiovascular

Diabetes Mellitus

Anti-infective

Others

Distribution Channel

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Region

North America

Europe

Asia Pacific

Latin America

Middle East & Africa

Frequently Asked Questions

What is the total market worth of polypill products market?

Polypill products market is expected to reach valuation of ~US$ 35 Bn by the end of 2027

What is the anticipated CAGR of the polypill products market in the forecast period?

Polypill products market is projected to expand at a CAGR of ~2% from 2019 to 2027

What are the key driving factors for the growth of the polypill products market?

Polypill products market is driven by rise in awareness about advanced therapeutics, and increase in patients with chronic diseases

Which region is expected to project the highest market share in the global polypill products market?

North America accounted for major share of the global polypill products market and the trend is anticipated to continue during the forecast period

Who are the key players in the global polypill products market?

Key players in the global polypill products market include Pfizer, Inc., AstraZeneca, Merck & Co., Inc. (Merck Sharp & Dohme Corp.), Janssen Pharmaceuticals, Inc.(Johnson & Johnson), Dr. Reddy’s Laboratories Ltd.

    1. Preface

        1.1. Market Definition and Scope

        1.2. Market Segmentation

        1.3. Key Research Objectives

        1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary: Global Polypill Products Market

    4. Market Overview

        4.1. Introduction

            4.1.1. Application/Definition

            4.1.2. Industry Evolution / Developments

        4.2. Overview

        4.3. Market Dynamics

            4.3.1. Drivers

            4.3.2. Restraints

            4.3.3. Opportunities

        4.4. Global Polypill Products Market Analysis and Forecast, 2017–2027

    5. Market Outlook

        5.1. Epidemiology of Cardiovascular Diseases, Diabetes Mellitus and Infectious Diseases 

        5.2. Pipeline Analysis

        5.3. Regulatory Scenario/Drug Approval Process, by Country/Sub-region

        5.4. Technological Advancements

    6. Global Polypill Products Market Analysis and Forecast, by Application

        6.1. Introduction & Definition

        6.2. Key Findings / Developments

        6.3. Global Polypill Products Market Value Forecast, by Application, 2017–2027

            6.3.1. Cardiovascular

            6.3.2. Diabetes Mellitus

            6.3.3. Anti-infective

            6.3.4. Others

        6.4. Global Polypill Products Market Attractiveness Analysis, by Application

    7. Global Polypill Products Market Analysis and Forecast, by Distribution Channel

        7.1. Introduction & Definition

        7.2. Key Findings / Developments

        7.3. Global Polypill Products Market Value Forecast, by Distribution Channel, 2017–2027

            7.3.1. Hospital Pharmacies

            7.3.2. Retail Pharmacies

            7.3.3. Online Pharmacies

        7.4. Global Polypill Products Market Attractiveness Analysis, by Distribution Channel

    8. Global Polypill Products Market Analysis and Forecast, by Region

        8.1. Key Findings

        8.2. Global Polypill Products Market Value Forecast, by Region

            8.2.1. North America 

            8.2.2. Europe 

            8.2.3. Asia Pacific 

            8.2.4. Latin America 

            8.2.5. Middle East & Africa 

        8.3. Global Polypill Products Market Attractiveness Analysis, by Region

    9. North America Polypill Products Market Analysis and Forecast

        9.1. Introduction

            9.1.1. Key Findings

        9.2. North America Polypill Products Market Value Forecast, by Application, 2017–2027

            9.2.1. Cardiovascular

            9.2.2. Diabetes Mellitus

            9.2.3. Anti-infective

            9.2.4. Others

        9.3. North America Polypill Products Market Value Forecast, by Distribution Channel, 2017–2027

            9.3.1. Hospital Pharmacies

            9.3.2. Retail Pharmacies

            9.3.3. Online Pharmacies

        9.4. North America Polypill Products Market Value Forecast, by Country, 2017–2027

            9.4.1. U.S.

            9.4.2. Canada

        9.5. North America Polypill Products Market Attractiveness Analysis 

            9.5.1. By Application

            9.5.2. By Distribution Channel

            9.5.3. By Country

    10. Europe Polypill Products Market Analysis and Forecast

        10.1. Introduction

            10.1.1. Key Findings

        10.2. Europe Polypill Products Market Value Forecast, by Application, 2017–2027

            10.2.1. Cardiovascular

            10.2.2. Diabetes Mellitus

            10.2.3. Anti-infective

            10.2.4. Others

        10.3. Europe Polypill Products Market Value Forecast, by Distribution Channel, 2017–2027

            10.3.1. Hospital Pharmacies

            10.3.2. Retail Pharmacies

            10.3.3. Online Pharmacies

        10.4. Europe Polypill Products Market Value Forecast, by Country/Sub-region, 2017–2027

            10.4.1. Germany

            10.4.2. U.K.

            10.4.3. France

            10.4.4. Spain

            10.4.5. Italy

            10.4.6. Rest of Europe

        10.5. Europe Polypill Products Market Attractiveness Analysis 

            10.5.1. By Application

            10.5.2. By Distribution Channel

            10.5.3. By Country/Sub-region

    11. Asia Pacific Polypill Products Market Analysis and Forecast

        11.1. Introduction

            11.1.1. Key Findings

        11.2. Asia Pacific Polypill Products Market Value Forecast, by Application, 2017–2027

            11.2.1. Cardiovascular

            11.2.2. Diabetes Mellitus

            11.2.3. Anti-infective

            11.2.4. Others

        11.3. Asia Pacific Polypill Products Market Value Forecast, by Distribution Channel, 2017–2027

            11.3.1. Hospital Pharmacies

            11.3.2. Retail Pharmacies

            11.3.3. Online Pharmacies

        11.4. Asia Pacific Polypill Products Market Value Forecast, by Country/Sub-region, 2017–2027

            11.4.1. China

            11.4.2. Japan

            11.4.3. India

            11.4.4. Australia & New Zealand

            11.4.5. Rest of Asia Pacific

        11.5. Asia Pacific Polypill Products Market Attractiveness Analysis 

            11.5.1. By Application

            11.5.2. By Distribution Channel

            11.5.3. By Country/Sub-region

    12. Latin America Polypill Products Market Analysis and Forecast

        12.1. Introduction

            12.1.1. Key Findings

        12.2. Latin America Polypill Products Market Value Forecast, by Application, 2017–2027

            12.2.1. Cardiovascular

            12.2.2. Diabetes Mellitus

            12.2.3. Anti-infective

            12.2.4. Others

        12.3. Latin America Polypill Products Market Value Forecast, by Distribution Channel, 2017–2027

            12.3.1. Hospital Pharmacies

            12.3.2. Retail Pharmacies

            12.3.3. Online Pharmacies

        12.4. Latin America Polypill Products Market Value Forecast, by Country/Sub-region, 2017–2027

            12.4.1. Brazil

            12.4.2. Mexico

            12.4.3. Rest of Latin America

        12.5. Latin America Polypill Products Market Attractiveness Analysis 

            12.5.1. By Application

            12.5.2. By Distribution Channel

            12.5.3. By Country/Sub-region

    13. Middle East & Africa Polypill Products Market Analysis and Forecast

        13.1. Introduction

            13.1.1. Key Findings

        13.2. Middle East & Africa Polypill Products Market Value Forecast, by Application, 2017–2027

            13.2.1. Cardiovascular

            13.2.2. Diabetes Mellitus

            13.2.3. Anti-infective

            13.2.4. Others

        13.3. Middle East & Africa Polypill Products Market Value Forecast, by Distribution Channel, 2017–2027

            13.3.1. Hospital Pharmacies

            13.3.2. Retail Pharmacies

            13.3.3. Online Pharmacies

        13.4. Middle East & Africa Polypill Products Market Value Forecast, by Country/Sub-region, 2017–2027

            13.4.1. GCC Countries

            13.4.2. South Africa

            13.4.3. Rest of Middle East & Africa

        13.5. Middle East & Africa Polypill Products Market Attractiveness Analysis 

            13.5.1. By Application

            13.5.2. By Distribution Channel

            13.5.3. By Country/Sub-region

    14. Competitive Landscape

        14.1. Market Player - Competition Matrix (By Tier and Size of companies)

        14.2. Market Share Analysis/Ranking, by Company, 2018

        14.3. Company Profiles

            14.3.1. Pfizer Inc. 

                14.3.1.1. Company Overview

                14.3.1.2. Company Financials

                14.3.1.3. Growth Strategies

                14.3.1.4. SWOT Analysis

            14.3.2. AstraZeneca

                14.3.2.1. Company Overview

                14.3.2.2. Company Financials

                14.3.2.3. Growth Strategies

                14.3.2.4. SWOT Analysis

            14.3.3. Merck & Co., Inc. (Merck Sharp & Dohme Corp)

                14.3.3.1. Company Overview

                14.3.3.2. Company Financials

                14.3.3.3. Growth Strategies

                14.3.3.4. SWOT Analysis

            14.3.4. Janssen Pharmaceuticals, Inc. (Johnson & Johnson)

                14.3.4.1. Company Overview

                14.3.4.2. Company Financials

                14.3.4.3. Growth Strategies

                14.3.4.4. SWOT Analysis

            14.3.5. Dr. Reddy’s Laboratories Ltd.

                14.3.5.1. Company Overview

                14.3.5.2. Company Financials

                14.3.5.3. Growth Strategies

                14.3.5.4. SWOT Analysis

            14.3.6. Cipla, Inc. 

                14.3.6.1. Company Overview

                14.3.6.2. Company Financials

                14.3.6.3. Growth Strategies

                14.3.6.4. SWOT Analysis

            14.3.7. Cadila Pharmaceuticals

                14.3.7.1. Company Overview

                14.3.7.2. Growth Strategies

                14.3.7.3. SWOT Analysis

            14.3.8. Grupo Ferrer International, S.A.

                14.3.8.1. Company Overview

                14.3.8.2. Growth Strategies

                14.3.8.3. SWOT Analysis

            14.3.9. Gebro Pharma GmbH 

                14.3.9.1. Company Overview

                14.3.9.2. Growth Strategies

                14.3.9.3. SWOT Analysis

            14.3.10. Gilead Sciences, Inc. 

                14.3.10.1. Company Overview

                14.3.10.2. Company Financials

                14.3.10.3. Growth Strategies

                14.3.10.4. SWOT Analysis

            14.3.11. Takeda Pharmaceutical Company Limited

                14.3.11.1. Company Overview

                14.3.11.2. Company Financials

                14.3.11.3. Growth Strategies

                14.3.11.4. SWOT Analysis

    List of Table

    Table 01: Global Polypill Products Market Value (US$ Mn) Forecast, by Application, 2017–2027

    Table 02: Global Polypill Products Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

    Table 03: Global Polypill Products Market Value (US$ Mn) Forecast, by Region, 2017–2027

    Table 04: North America Polypill Products Market Value (US$ Mn) Forecast, by Application, 2017–2027

    Table 05: North America Polypill Products Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

    Table 06: North America Polypill Products Market Value (US$ Mn) Forecast, by Country, 2017–2027

    Table 07: Europe Polypill Products Market Value (US$ Mn) Forecast, by Application, 2017–2027

    Table 08: Europe Polypill Products Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

    Table 09: Europe Polypill Products Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

    Table 10: Asia Pacific Polypill Products Market Value (US$ Mn) Forecast, by Application, 2017–2027

    Table 11: Asia Pacific Polypill Products Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

    Table 12: Asia Pacific Polypill Products Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

    Table 13: Latin America Polypill Products Market Value (US$ Mn) Forecast, by Application, 2017–2027

    Table 14: Latin America Polypill Products Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

    Table 15: Latin America Polypill Products Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

    Table 16: Middle East & Africa Polypill Products Market Value (US$ Mn) Forecast, by Application, 2017–2027

    Table 17: Middle East & Africa Polypill Products Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

    Table 18: Middle East & Africa Polypill Products Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

    List of Figure

    Figure 01: Global Polypill Products Market Value (US$ Mn) and Distribution (%), by Region, 2018 and 2027

    Figure 02: Global Polypill Products Market Value (US$ Mn), by Application, 2018

    Figure 03: Global Polypill Products Market Value Share Analysis, by Distribution Channel, 2018

    Figure 04: Market Overview

    Figure 05: Global Polypill Products Market Value Share, by Application, 2018

    Figure 06: Global Polypill Products Market Value Share, by Distribution Channel, 2018

    Figure 07: Global Polypill Products Market Value Share, by Region, 2018

    Figure 08: Global Polypill Products Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2027

    Figure 09: Global Polypill Products Market Value Share Analysis, by Application, 2018 and 2027

    Figure 10: Global Polypill Products Market Value (US$ Mn) and Y-o-Y Growth, by Cardiovascular, 2017–2027

    Figure 11: Global Polypill Products Market Value (US$ Mn) and Y-o-Y Growth, by Diabetes Mellitus, 2017–2027

    Figure 12: Global Polypill Products Market Value (US$ Mn) and Y-o-Y Growth, by Anti-infective, 2017–2027

    Figure 13: Global Polypill Products Market Value (US$ Mn) and Y-o-Y Growth, by Others, 2017–2027

    Figure 14: Global Polypill Products Market Attractiveness Analysis, by Application, 2019–2027

    Figure 15: Global Polypill Products Market Value Share Analysis, by Distribution Channel, 2018 and 2027

    Figure 16: Global Polypill Products Market Value (US$ Mn) and Y-o-Y Growth, by Hospital Pharmacies, 2017–2027

    Figure 17: Global Polypill Products Market Value (US$ Mn) and Y-o-Y Growth, by Retail Pharmacies, 2017–2027

    Figure 18: Global Polypill Products Market Value (US$ Mn) and Y-o-Y Growth, by Online Pharmacies, 2017–2027

    Figure 19: Global Polypill Products Market Attractiveness Analysis, by Distribution Channel, 2019–2027

    Figure 20: Global Polypill Products Market Value Share Analysis, by Region, 2018 and 2027

    Figure 21: Global Polypill Products Market Attractiveness Analysis, by Region, 2019–2027

    Figure 22: North America Polypill Products Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027

    Figure 23: North America Polypill Products Market Value Share Analysis, by Application, 2018 and 2027

    Figure 24: North America Polypill Products Market Attractiveness Analysis, by Application, 2019–2027

    Figure 25: North America Polypill Products Market Value Share Analysis, by Distribution Channel, 2018 and 2027

    Figure 26: North America Polypill Products Market Attractiveness Analysis, by Distribution Channel, 2019 -2027

    Figure 27: North America Polypill Products Market Value Share Analysis, by Country, 2018 and 2027

    Figure 28: North America Polypill Products Market Attractiveness Analysis, by Country, 2019–2027

    Figure 29: Europe Polypill Products Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027

    Figure 30: Europe Polypill Products Market Value Share Analysis, by Application, 2018 and 2027

    Figure 31: Europe Polypill Products Market Attractiveness Analysis, by Application, 2019–2027

    Figure 32: Europe Polypill Products Market Value Share Analysis, by Distribution Channel, 2018 and 2027

    Figure 33: Europe Polypill Products Market Attractiveness Analysis, by Distribution Channel, 2019 -2027

    Figure 34: Europe Polypill Products Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

    Figure 35: Europe Polypill Products Market Attractiveness Analysis, by Country/Sub-region, 2019–2027

    Figure 36: Asia Pacific Polypill Products Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027

    Figure 37: Asia Pacific Polypill Products Market Value Share Analysis, by Application, 2018 and 2027

    Figure 38: Asia Pacific Polypill Products Market Attractiveness Analysis, by Application, 2019–2027

    Figure 39: Asia Pacific Polypill Products Market Value Share Analysis, by Distribution Channel, 2018 and 2027

    Figure 40: Asia Pacific Polypill Products Market Attractiveness Analysis, by Distribution Channel, 2019 -2027

    Figure 41: Asia Pacific Polypill Products Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

    Figure 42: Asia Pacific Polypill Products Market Attractiveness Analysis, by Country/Sub-region, 2019–2027

    Figure 43: Latin America Polypill Products Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027

    Figure 44: Latin America Polypill Products Market Value Share Analysis, by Application, 2018 and 2027

    Figure 45: Latin America Polypill Products Market Attractiveness Analysis, by Application, 2019–2027

    Figure 46: Latin America Polypill Products Market Value Share Analysis, by Distribution Channel, 2018 and 2027

    Figure 47: Latin America Polypill Products Market Attractiveness Analysis, by Distribution Channel, 2019 -2027

    Figure 48: Latin America Polypill Products Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

    Figure 49: Latin America Polypill Products Market Attractiveness Analysis, by Country/Sub-region, 2019–2027

    Figure 50: Middle East & Africa Polypill Products Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027

    Figure 51: Middle East & Africa Polypill Products Market Value Share Analysis, by Application, 2018 and 2027

    Figure 52: Middle East & Africa Polypill Products Market Attractiveness Analysis, by Application, 2019–2027

    Figure 53: Middle East & Africa Polypill Products Market Value Share Analysis, by Distribution Channel, 2018 and 2027

    Figure 54: Middle East & Africa Polypill Products Market Attractiveness Analysis, by Distribution Channel, 2019 -2027

    Figure 55: Middle East & Africa Polypill Products Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

    Figure 56: Middle East & Africa Polypill Products Market Attractiveness Analysis, by Country/Sub-region, 2019–2027

    Figure 57: Market Position Analysis, 2018, by Tier and Size of the Company

    Figure 58: Pfizer, Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2018

    Figure 59: Pfizer, Inc. Breakdown of Net Sales, by Geography, 2018

    Figure 60: Pfizer, Inc. Breakdown of Net Sales, by Business Segments (%), 2018

    Figure 61: Pfizer, Inc. R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015–2018

    Figure 62: AstraZeneca Revenue (US$ Mn) and Y-o-Y Growth (%), 2016–2018

    Figure 63: AstraZeneca Breakdown of Net Sales (%), by Geography, 2018

    Figure 64: AstraZeneca R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2016–2018

    Figure 65: AstraZeneca Respiratory Segment Revenue (US$ Mn) and Y-o-Y Growth (%), 2016–2018

    Figure 66: Merck & Co., Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2018

    Figure 67: Merck & Co., Inc. Breakdown of Net Sales (%), by Region/Country, 2018

    Figure 68: Merck & Co., Inc. Revenue Breakdown of Net Sales (%), by Segment, 2018

    Figure 69: Merck & Co., Inc. R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015–2018

    Figure 70: Johnson & Johnson Pharmaceutical Segment Revenue (US$ Mn) and Y-o-Y Growth (%), 2016–2018

    Figure 71: Johnson & Johnson Breakdown of Net Sales (%), of Pharmaceutical Segment by Region/Country, 2018

    Figure 72: Johnson & Johnson Revenue Breakdown of Net Sales (%), by Pharmaceutical Segment, 2018

    Figure 73: Johnson & Johnson, Pharmaceutical Segment R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2016–2018

    Figure 74: Dr. Reddy’s Laboratories Ltd. Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2018

    Figure 75: Dr. Reddy’s Laboratories Ltd. Breakdown of Net Sales (%) of Global Generics Business Segment, by Region/Country, 2018

    Figure 76: Dr. Reddy’s Laboratories Ltd. Revenue Breakdown of Net Sales (%), by Global Generics Segment, 2018

    Figure 77: Dr. Reddy’s Laboratories Ltd. R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2016–2018

    Figure 78: Cipla Inc., Revenue (US$ Mn), 2017–2018

    Figure 79: Cipla Inc., Breakdown of Net Sales (%), by Region, 2018

    Figure 80: Cipla Inc., Breakdown of Net Sales (%), by Business Segment, 2018

    Figure 81: Gilead Sciences, Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2018

    Figure 82: Genvoya Breakdown of Net Sales (%), by Region/Country, 2018

    Figure 83: Stribild Breakdown of Net Sales (%), by Region/Country, 2018

    Figure 84: Gilead Sciences, Inc. R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2017–2018

    Figure 85: Takeda Pharmaceutical Company Limited Revenue (US$ Mn) and Y-o-Y Growth (%), 2016–2019

    Figure 86: Takeda Pharmaceutical Company Limited Breakdown of Net Sales (%), by Region/Country, 2019

    Figure 87: Takeda Pharmaceutical Company Limited R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2017–2019

Copyright © Transparency Market Research, Inc. All Rights reserved

Polypill Products Market

Schedule a Call